Lightshift Energy Secures up to $40 Million Corporate Credit Facility From Aiga Capital Partners to Accelerate Energy Storage Portfolio
The facility will serve as a strategic tool to support Lightshift's rapidly growing portfolio by funding interconnection and power purchase agreement ('PPA') security requirements, equipment deposits, and other uses. The expandable credit line comes at a critical time as Lightshift transitions a significant portion of its pipeline into construction during the second half of 2025 and into 2026.
'This financing milestone strengthens our balance sheet and positions Lightshift to execute with speed and certainty as we bring more of our high-impact projects online,' said Rory Jones, Co-Founder and Managing Partner at Lightshift Energy. 'We are pleased to partner with Aiga, whose innovative approach to structured credit supports our mission to advance a more resilient, capable and lower-cost grid.'
'At Aiga, we are committed to delivering creative, scalable financing solutions to best-in-class developers leading the energy transition,' said Angel Fierro, Managing Partner at Aiga Capital Partners. 'Lightshift has demonstrated both the technical expertise and disciplined execution needed to drive the next generation of battery storage deployment, and we are excited to support their ambitious build-out.'
With this transaction, Lightshift Energy further establishes itself as a trusted partner to utilities, large-load customers, and communities seeking reliable and flexible clean power solutions.
About Lightshift Energy
Lightshift Energy is a utility-scale energy storage project developer, owner and operator headquartered in Arlington, Virginia. Founded in 2019, Lightshift is developing a diverse, multi-gigawatt pipeline of energy storage projects, located throughout the U.S. With leading energy storage analytics, application design, finance, and development expertise, Lightshift deploys dynamic, multi-use energy storage projects that maximize value for utilities and other partners, while reinvesting directly into the communities where their projects are located. For more information, please visit www.lightshift.com.
About Aiga Capital Partners
Aiga is a minority-owned investment platform supporting the energy transition with structured debt and equity solutions for developers of sustainable assets in North America. In an effort to contribute towards net zero emission goals, its strategy targets growth capital deployment opportunities in renewable energy, energy storage and other sustainable infrastructure sectors. To learn more, visit: www.aigacapital.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
an hour ago
- Epoch Times
The Hidden Math That Makes Some Australians Poorer for Working Harder
AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles
Business Upturn
an hour ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Honasa Consumer surges over 8% after Q1 earnings beat and brokerage upgrades
By Aditya Bhagchandani Published on August 13, 2025, 09:24 IST Shares of Honasa Consumer Ltd., the parent company of Mamaearth, surged 8.15% to ₹291.25 on Wednesday, August 13, following the announcement of its June quarter (Q1 FY26) results after market hours on Tuesday. This marks the second consecutive session of gains for the stock. The company posted a net profit of ₹41 crore for Q1 FY26, up 2.7% year-on-year, while revenue grew 7% YoY to ₹595 crore. EBITDA slipped 1% YoY to ₹46 crore, with margins holding at 7.7%. Hong Kong-based brokerage CLSA upgraded Honasa to 'Outperform' and raised its price target to ₹333, noting Q1 revenue growth of 7.4% YoY in line with expectations, alongside underlying volume growth of 10.5% YoY. CLSA highlighted a sequential EBITDA margin expansion of 264 bps to 7.7%, delivering a 47% beat versus its estimates and a 44% beat on consensus expectations. Management guided for an EBITDA margin of around 7% in FY26, with 100-150 bps expansion annually over the next 4–5 years. CLSA also raised its FY26–FY28 earnings estimates by 15–26%. Jefferies maintained a 'Buy' rating with a price target of ₹400, citing positive margin surprises. The brokerage acknowledged that unseasonal rains impacted sunscreen sales but noted that sequential EBITDA margin improvement and outperformance versus expectations were key positives. Jefferies added that while new brands are scaling slowly, Mamaearth remains the primary growth driver. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
